Table 1 Subject details of patients receiving radionuclide therapy with [177 Lu]Lu-DOTAZOL
PT1 | PT2 | PT3 | PT4 | Mean | SD | |
|---|---|---|---|---|---|---|
Age | 83 | 66 | 64 | 64 | 69.25 | 9.22 |
BSA | 1.922 | 1.976 | 1.979 | 1.979 | 1.964 | 0.028 |
Hemoglobin (g/dl) | 14.3 | 9.6 | 13.1 | 12.6 | 12.4 | 2 |
Thrombocytes (G/l) | 187 | 394 | 226 | 189 | 249 | 98.32 |
Leucocytes (G/l) | 5.47 | 9.77 | 5.37 | 3.35 | 5.99 | 2.70 |
Hematocrit | 0.4 | 0.4 | 0.4 | 0.37 | 0.39 | 0.02 |
Dose (MBq) | 6000 | 6000 | 5873 | 6000 | 5968.25 | 63.50 |
Tumor | mCRPC | mCRPC | Bronchial carcinoma | Bronchial carcinoma | ||
Previous therapies received | Degarelix/denusumab [17777Lu]Lu-PSMA-617 | Local Irradiation/docetaxel leuprorelin acetate, abiraterone/denosumab | Carboplatin/denosumab, nivolumab | Carboplatin/denosumab, nivolumab | ||
Extent of metastases | Extensive | Extensive | Extensive | Extensive | ||
ECOG status | 0 | 0 | 0 | 0 |